A Qualified Person Responsible for Pharmacovigilance (QPPV) is the designated individual who has overall responsibility for an organisation’s pharmacovigilance (PV) system. In practice, the role exists to ensure the marketing authorisation holder (MAH) can demonstrate continuous oversight of safety monitoring and PV compliance across its products and activities, not just individual tasks within the PV function.
Where is a QPPV required, and what must the MAH have in place?
In the EU/EEA context, the MAH is expected to have a QPPV arrangement in place as part of its PV system. In the UK context, organisations are expected to operate with a UK QPPV. An EU QPPV can be accepted alongside a UK national contact person. Many other regions require a local person for pharmacovigilance (LPPV).
The QPPV is not just a named person; it also includes the conditions that make oversight credible, such as clarity on where the QPPV sits in the organisation, the authority to act, sufficient support and resources, and an approach that maintains continuity and availability rather than treating the role as an occasional sign-off point. A useful way to think about this is that the MAH owns the PV system, and the QPPV operates as the accountable individual within that system. If the organisation cannot show how the QPPV is empowered, supported, and kept informed, the appointment alone does not achieve what the role is meant to deliver.
What does a QPPV do day to day?
The QPPV’s remit is usually easier to manage when you group it into a small number of responsibility areas. Those areas collectively demonstrate PV system control and safety oversight, even though many underlying activities are delivered by wider PV teams and partners.
The role of the QPPV is to maintain accountable oversight of how pharmacovigilance is run (the system) and what it is showing (the safety profile), and to ensure issues are identified, escalated, and acted on in a controlled way.
For scanning, the role is often described along the following lines:
| Responsibility area | What it typically covers | What you can usually evidence |
| PV system oversight | The PV system exists, functions, and is supported by a quality framework, including governance, escalation, vendor oversight, and corrective actions | Governance cadence and minutes, escalation logs, oversight packs/metrics, CAPA tracking, audit and inspection outputs |
| Oversight of the safety profile | Ongoing awareness of known and emerging safety concerns and what they mean for benefit–risk and risk minimisation | Safety governance records, documented escalations and decisions, traceable follow-up actions |
| Stewardship of key PV artefacts | Oversight of core PV documentation and deliverables, including maintaining alignment between stated processes and operational reality (for example, the PSMF) | Version control, review records, controlled document lists, evidence that artefacts reflect current practice |
| PV activities delivered through teams and partners | Oversight of how case processing, reporting, signal work, and periodic activities are performed, including how outsourced activities are governed | PV agreements, defined data exchange processes, vendor oversight records, quality monitoring outputs |
The key point is that the QPPV’s accountability sits above individual tasks. The organisation should be able to show how the QPPV stays informed, how issues reach them early enough to act, and how oversight translates into decisions and controlled follow-up.
What does ‘oversight’ mean in practice?
‘Oversight’ can sound abstract until you pin it to the inputs a QPPV needs in order to stay in control. Oversight means the QPPV is not surprised by safety issues, system changes, or compliance risks, because the organisation has built dependable routes for the right information to reach them in time.
That typically requires regular, structured updates and access to the underlying trackers and documentation, not only summary statements. The information flow often spans safety surveillance and signal topics, PV agreements and vendor oversight, PV system changes, audit and inspection outcomes, and operational indicators that suggest emerging strain in the system.
Because those inputs sit across functions, the QPPV role tends to work best when it is embedded in cross-functional governance rather than isolated within PV. Clear meeting cadence, defined escalation triggers, and traceable records of what was raised and decided help turn ‘oversight’ into something you can evidence.
To keep information flow practical, it can help to define a simple view of ‘what the QPPV needs from whom’. For example:
| Function/interface | What the QPPV typically needs to stay informed |
| Senior management | Resourcing decisions, organisational changes, and clear escalation routes for PV risks |
| Clinical and clinical operations | Visibility of relevant clinical trial safety developments and changes that affect safety oversight |
| Regulatory | Planned and emergent regulatory interactions and any commitments that affect PV activities |
| Safety science/medical safety | Signal discussions, safety evaluations, and benefit–risk considerations |
| PV operations and case processing | Operational performance, backlogs/pressure points, compliance metrics, and escalation of critical cases |
| Quality and compliance | Audit outcomes, CAPA status, inspection readiness activities, and quality signals |
| Partners and vendors | Contracted responsibilities, PV agreement updates, and vendor oversight findings |
Can a QPPV delegate tasks or appoint a deputy?
A QPPV can typically delegate specific tasks, but delegation does not transfer accountability. The intent is that the QPPV remains responsible for ensuring the task is performed appropriately and that the outcome is visible within the wider PV system.
This is where it helps to separate responsibility, authority, and accountability. Individuals or teams may have responsibility for completing defined activities, and may be given authority to act within agreed bounds. The QPPV remains accountable for the functioning of the PV system and for maintaining the level of oversight the role requires.
Where the QPPV has not completed basic medical training, the MAH must ensure that the QPPV is assisted by a medically trained person, which should be duly documented.
Where deputisation is used, it should be clearly defined so there is no uncertainty about who acts when the QPPV is unavailable, what decisions can be taken, and how continuity is maintained.
What typically goes wrong in inspections?
Inspection findings commonly cluster around whether the QPPV arrangement works in practice, not whether it exists on paper. Recurring themes include gaps in coverage or continuity, problems with notification and maintenance of QPPV details, unclear role definition or insufficient authority, and evidence that oversight is not effective.
Another frequent issue is weak traceability: an organisation may describe governance and escalation routes, but cannot show how information reached the QPPV, what decisions were made, and how follow-up actions were controlled. Training also appears as a practical vulnerability when records are incomplete, role-based expectations are unclear, or non-PV functions do not recognise what they must report and how quickly. Taken together, these findings point to the same core risk: a QPPV who is expected to be accountable without being equipped with reliable inputs, authority, and documented support.
What makes someone ‘qualified’ and what training is expected across the organisation?
Competence is usually described in terms of relevant experience and PV knowledge, supported by the ability to operate credibly with senior stakeholders and regulators. The role also relies on strong communication and organisational skills, because oversight is achieved through governance, escalation, and follow-through rather than personal completion of every activity. It is expected that appropriate expertise is available to the QPPV in the areas of medicine, pharmaceutical sciences, epidemiology and biostatistics.
Training does not stop with the QPPV. A PV system depends on broader organisational behaviours, including prompt internal reporting of safety information and consistent execution of PV procedures by staff and partners. That is why role-appropriate training, refreshers, and traceable training records matter as part of demonstrating system control and inspection readiness.
Conclusion
If you are reviewing QPPV coverage, start with the basics but test them for operational reality. Confirm there is a named, appropriately qualified QPPV, and a continuity arrangement, then check whether the role has defined authority, resources, and an evidenced position in governance. Next, pressure-test ‘oversight’: what information is expected to reach the QPPV, how often, through what forums, and with what traceable record of decisions and actions.
Finally, look at delegation and training through an inspection lens. Delegation should be documented and controlled without diluting accountability, and training should support the behaviours that keep the PV system responsive, including outside the PV function. Those checks do not replace detailed PV system review, but they usually surface whether the QPPV role is set up as a living control function or a nominal title.
About QVigilance
We are a specialised pharmacovigilance service provider, offering comprehensive pharmacovigilance services to sponsors of clinical trials and manufacturers of authorised medicinal products. QVigilance is adept in supporting customers establishing a compliant pharmacovigilance system to support our customers’ products and safeguard their patients.
FAQs
What is an EU QPPV?
In the EU regulatory context overseen by the EMA, a QPPV is the MAH’s designated individual accountable for pharmacovigilance system oversight and for maintaining an overview of the safety profile.
What is the role of QPPV?
The role of the QPPV is to provide accountable oversight of the PV system and the product safety profile, ensuring issues are identified, escalated, and acted on through controlled governance and follow-up.
What are the obligations of QPPV?
The QPPV’s obligations centre on maintaining oversight of the PV system and safety profile, and on ensuring key PV documentation and activities remain inspection-ready and aligned with operational reality. These obligations are only workable when the MAH provides the authority, resources, and information flow that support continuous oversight.